TRUS-biopsy Poorly Detects Prostate Cancer

Share this content:
Transrectal ultrasound-guided prostate biopsy poorly detects and rules out clinically significant prostate cancer.
Transrectal ultrasound-guided prostate biopsy poorly detects and rules out clinically significant prostate cancer.

CHICAGO — Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer, whereas multi-parametric magnetic resonance imaging (MP-MRI) can identify 27% of men who might safely avoid unnecessary biopsy, a study presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting showed.1

"The current diagnosis pathway can result in various errors: clinically indolent cancers are identified by chance; clinically significant lesions are missed; important cancers are incorrectly classified as unimportant; and men undergo whole-gland treatment, which carries harm," said co-investigator and presenter Hashim Ahmed, PhD, an MRC clinician scientist at University College London Hospitals in the United Kingdom.

Because MP-MRI as a triage test might allow men to avoid unnecessary TRUS-biopsy, since men with an elevated PSA do not have clinically significant prostate cancer, researchers evaluated the accuracy of MP-MRI followed by TRUS-biopsy vs template prostate mapping biopsy (TPM-biopsy) as an accurate reference test.

For the prospective, paired-cohort confirmatory PROMIS study, investigators enrolled 740 men with an elevated PSA up to 15 ng/mL who had not undergone prior biopsy.

All men underwent MP-MRI followed by both TRUS-biopsy and TPM-biopsy. All patients and physicians were blinded to MP-MRI reports and radiologists were not present at the time of biopsy; pathologists reading biopsy reports were blinded to MP-MRI reports; and TPM-biopsy and TRUS-biopsy reports were sent to different expert uro-pathologists.

Among the 576 evaluable patients who underwent all 3 diagnostic tests, results showed that the reference TPM-biopsy detected clinically significant prostate cancer in 40% of patients. For MP-MRI, sensitivity was 93% (95% CI, 88-96), specificity was 41% (95% CI, 36-46), positive predictive value was 51% (95% CI, 46-56), and negative predictive value was 89% (95% CI, 83-94).

"MP-MRI can identify more than 90% of men with clinically significant prostate cancers," Dr Ahmed said.

In contrast, sensitivity for TRUS-biopsy was 48% (95% CI, 42-55), specificity was 96% (95% CI, 94-98), positive predictive value was 90% (95% CI, 83-94), and negative predictive value was 74% (95% CI, 69-78).

"TRUS-biopsy has poor attributes for a diagnostic test," Dr Ahmed noted.

Researchers found that TRUS-biopsy was significantly less sensitive than MP-MRI (OR, 0.06; 95% CI, 0.02-0.12; P≤.0001). Further, TRUS-biopsy had significant worse negative predictive value than MP-MRI (OR, 0.34; 95% CI, 0.21-0.55; P<.0001).

RELATED: Prostate Cancer Patient-Physician Communication Improves Health-related Quality of Life

The investigators determined that using MP-MRI as a triage test would avoid a primary biopsy in 27% of men at the minimum but detect 18% more cases of clinically significant cancer than the standard TRUS-biopsy.

"The high sensitivity and negative predictive value of prostate MP-MRI at 1.5 Tesla justify its use as a triage test to identify those men who might avoid a primary biopsy," Dr Ahmed explained. "The low specificity and positive predictive value of prostate MP-MRI indicated that men with suspicious MP-MRI still require a biopsy."


  1. Ahmed HU, Bosaily AE, Brown LC, et al. The PROMIS study: A paired-cohort, blinded confirmatory study evaluating the accuracy of multi-parametric MRI and TRUS biopsy in men with an elevated PSA. J Clin Oncol. 2016; 34 (suppl; abstr 5000).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs